Hemostemix is a public clinical-stage company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments.
Welcome to my first-ever blog post, as I share milestones in the Hemostemix story with patients, employees, and investors.
Assuming the roles of President and CEO of Hemostemix required me to evaluate the company’s potential through the eyes of investors. I saw a solid foundation on which to build that includes:
- Strong science with a unique technology platform supported by more than 50 patents
- Extensive patient exposure and promising safety data in treating hundreds of patients with our lead product, angiogenic cell precursor (ACP)-01